Despite this initial controversial finding, the subsequent obesity GWAS have been extremely successful. Common variants at two loci, fat mass and obesity associated gene (FTO) [11, 12] : In addition to variants at seven loci that had previously not been associated with obesity, both FTO and MC4R were reconfirmed; furthermore, the two obesity candidate genes BDNF and SH2B1 were identified [1].
Despite this initial controversial finding, the subsequent obesity GWAS have been extremely successful. Common variants at two loci, fat mass and obesity associated gene (FTO) [11, 12] and MC4R [13] , have reproducibly been associated with increased BMI in humans. Both variants together explain approximately 0.5% of the BMI variance. The three novel studies analyzed more than 150,000 (!) individuals in total for genetic variants relevant in body weight regulation: -One GWAS was performed with 305,846 SNPs typed in 25,344 Icelandic, 2,998 Dutch, 1,890 European American and 1,160 African American subjects and combined with results previously published by the Diabetes Genetics Initiative (DGI) based on 3,024 Scandinavians. 43 variants in 19 regions were selected for follow-up in 5,586 Danish individuals. The results were compared with the results of the obesity GWAS of the GIANT consortium [2] (see below).
In eleven chromosomal regions a total of 29 variants, some of these correlated, reached a genome-wide significance threshold of p < 1.6 × 10 -7
: In addition to variants at seven loci that had previously not been associated with obesity, both FTO and MC4R were reconfirmed; furthermore, the two obesity candidate genes BDNF and SH2B1 were identified [1] .
-In parallel a meta-analysis of 15 GWAS for BMI (n = 32,387) was performed by the GIANT consortium based on approximately 2.4 million genotyped or imputed SNPs.
The top 35 signals were followed up in 14 additional cohorts (45,018 probands who were de novo genotyped and analysis of these SNPs in another 14,064 individuals already genotyped as part of other GWAS). A strong confirmation was detected for FTO and MC4R. Additionally, six novel loci were identified (p < 5 × 10 -8 ): TMEM18, KCTD15, GNPDA2, SH2B1, MTCH2, and NEGR1 (where a 45-kb deletion CNV is the candidate variant). Several of these Is it all in the genes? The unravelling of the genetics of obesity has made a major leap in the last 2 months. In the latest issues of Nature Genetics (both print and online versions), three papers reported novel obesity genes with small effects on human body weight [1] [2] [3] . The Icelandic company deCODE [1] and the Genetic Investigation of ANthropometric Traits (GIANT) consortium [2] started off with online versions of novel findings at the end of 2008; the French group headed by Philippe Froguel [3] just published their results. It is now well accepted that obesity results from interactions of genetic and environmental factors. More than 50% of the variance of body weight has been attributed to genetic factors [4] . Genome-wide linkage studies and candidate gene analyses have been performed for roughly 15 years. Some (extremely) rare monogenic forms of obesity with very large effect sizes were discovered mainly via the candidate gene approach based on rodent obesity models; mutations in the melanocortin-4 receptor gene (MC4R), which in adult heterozygous carriers account for an excess of 15 to 30 kg [5] , occur in approximately 1% of obese adults and in 2-6% of obese children [6] . Most of the respective genes are expressed in the CNS. In contrast, a vast number of association studies of obesity candidate genes has not led to clear-cut results. The respective findings were either only reported once or were not unequivocally confirmed in independent study groups [e.g . 7] . This situation changed about 2.5 years ago, when the first genome-wide association study (GWAS) for obesity became available [8] . DNA-chip technology has made simultaneous high throughput genotying of up to 2,000,000 genetic data per person (single nucleotide polymorphisms (SNPs) and copy number variations (CNVs)) feasible and affordable. Whether or not genetic variation of insulin-induced gene 2 (INSIG2) entails an effect on body weight is currently viewed controversially [9] ; an effect may potentially be discernible in extreme obesity only [10] .
presumptive 'obesity' genes (the variants actually explain BMI variance) are highly expressed and/or known to play a role in the function of the CNS. As such, the role of the CNS in predisposition to obesity is underscored. The effect of the variants on BMI ranged from 0.06 to 0.33 kg/m 2 (table 1) per allele, which corresponds to 173-954 g in weight per allele in adults who are approximately 170 cm tall. Together, the six newly discoverd loci account for 0.40% and in combination with FTO and MC4R for a total of 0.84% of the BMI variance. The combined impact of these loci on BMI was also estimated: Individuals with 13 or more obesity-predisposing alleles across the eight loci The term nearest gene does not necessarily imply that genetic variation of this gene(s) underlies the detected association. were on average 1.46 kg/m 2 (equivalent to 3.7-4.7 kg for an adult 160-180 cm in height) heavier than those individuals with less than 3 of these alleles [2]. -Most recently, 38 markers of a GWAS based on 1,380
Europeans with early-onset and morbid adult obesity and 1,416 age-matched normal-weight controls showed strong association with obesity and were further evaluated in 14,186 European subjects [3] . In addition to FTO and MC4R, significant association with obesity was detected for three new risk loci in the endosomal/lysosomal NiemannPick C1 gene (NPC1; p = 2.9 × 10 -7 ), near the transcription factor c-MAF gene (MAF, p = 3.8 × 10 -13 ), and near the phosphotriesterase-related gene (PTER; p = 2.1 × 10 -7 ). Additionally, candidate genes were analyzed in the GWAS data set. Interestingly, the first polygenic variant for weight regulation confirmed in large samples encompassing thousands of subjects (V103I of the MC4R) [14] [15] [16] was, among other genes, confirmed (p = 4.2 × 10 -4 ).
In conclusion, what have we learnt? i) Genetic variation of genes expressed in the CNS plays a prominent role in BMI variation: This finding is not unexpected due to the fact that approximately 50% of all human genes are thought to be centrally expressed. Furthermore, the role of the brain in energy balance had previously been established [9] . ii) Effect sizes are small and at best explain a few hundred grams. For the detection and confirmation of such variants several thousand probands are required; more are required if population-based individuals are screened, less if obese cases and lean controls are analyzed. What do we still not know? If genetic variation at the DNA level indeed accounts for roughly 50-70% of the BMI variation, we have at least 49% to go. It seems realistic to assume that the currently detected variants represent the tip of the iceberg, implying that potentially effect sizes of variants to be detected in the future will be even smaller. Obviously, very large sample sizes will be required to pick up these signals and to independently confirm them. Currently, there are hardly any published data pertaining to CNV in obesity. Does BMI heritability result from the effect of hundreds of alleles many of which account for less than 50 g? Accordingly, we would have substantial genetic heterogeneity among obese (lean) individuals. And if so, simplistic ideas of genotype-phenotype correlations would have to be dismissed; the clinical implications become more uncertain the more gene variants with (very) small effect sizes exist. Are we missing out on infrequent alleles with stronger effect sizes which cannot readily be picked up in GWAS? Are many relevant variants not appropriately represented using current DNA-chip technology? A disconcerting idea pertains to genotype-environment interactions. Maybe these can be rather specific based on the genotype (combination of all relevant alleles) of an individual? Whereas formal genetic studies have taught us that non-additive factors play a prominent role in BMI heritability estimates [17] , the currently known variants seemingly act in an additive manner only. Finally, do we have to think about other genetic mechanisms contributing to interindividual BMI variation? Two recent papers give hints: i) Turnbaugh et al. [18] analyzed the microbionta (ensemble of microbes in the human gut) in female mono-and dizygotic twins concordant for leanness or obesity. Obesity was associated with phylum-level changes in the microbiota, reduced bacterial diversity and altered representation of bacterial genes and metabolic pathways. Hence, deviations from a core functional microbiome are associated with different physiological states (obese compared with lean; [18] ). ii) Twin studies have provided the basis for genetic and epidemiological studies in human complex traits. Epigenetic factors can well contribute to phenotypic outcomes. Recently, the first annotation of epigenetic metastability of 6,000 unique genomic regions was described in monozygotic (MZ) twins. A comparison of matched MZ and dizygotic (DZ) twins showed significantly higher epigenetic difference in buccal cells of DZ co-twins (p = 1.2 × 10 -294 ). Although such higher epigenetic discordance in DZ twins can result from DNA sequence differences, in silico SNP analyses and animal studies favored the hypothesis that it is due to epigenomic differences in the zygotes. These data suggest that molecular mechanisms of heritability may not be limited to DNA sequence differences [19] . In conclusion, obesity is truly complex, and easy answers are not at hand. Did we expect anything else?
On the Contents of This Issue
Let me wish our readers a belated Happy New Year! Please let us point out that this issue marks the first anniversary of Obesity Facts. As of now, Obesity Facts has received a total of 99 manuscripts. Of these, 51 have been published or are in press. and 16 have been rejected; 32 are currently under review. Authors from a total of 25 countries have allowed us to review their work. The collaboration with EASO has been successful; we look forward to the next Editorial Board meeting during the 17th European Congress on Obesity (Amsterdam, May 6-9, 2009). We are compiling the application for a listing in Medline as we are acutely aware of the necessity to get Obesity Facts listed as soon as possible. In the following, we would like to briefly take you through the contents of the current issue. How do daily newspapers report on obesity-related issues? Anja Hilbert (Marburg, Germany) and Jens Ried [1] identified 222 articles on human overweight in a total 1,563 issues of five high-circulation German daily newspapers in 2006. The articles were subjected to a quantitative content analysis. The single tabloid newspaper provided the most incorrect information about obesity; the information in two local newspapers proved to be less negative and less catastrophizing. The national newspapers presented more attributions of obesity to internal and controllable causes. The authors conclude that the German newspapers may very well be contributing to stigmatization of obese individuals. We are all well familiar with the term bariatric surgery. However, what about bariatric psychology? Gerbrand van Hout (Eindhoven, the Netherlands) and Guus van Heck [2] urge that apart from weight loss and improvement or cure of comorbid conditions, bariatric surgery should also lead to improvements in eating behavior, psychosocial variables, and quality of life (QoL). The authors recommend that mental health professionals should be part of the process of evaluation and treatment of bariatric surgery patients. This is deemed all the more important because of the wellestablished role of psychosocial factors in the outcomes of bariatric surgery, the impact of psychosocial variables on quality of life after surgery, and the fact that the operation can profoundly modify the psychological and social situation. Most Dutch hospitals have a multidisciplinary selection process which includes a mental health specialist. Those topics that have been most frequently discussed by Dutch mental health specialists in preoperative psychological interviewing are delineated in the this article. Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies in women of fertile age affecting up to 6-7% of this population. The principle features are androgen excess, ovulatory dysfunction, and polycystic ovaries. Between 30 and 70% of women with PCOS are obese, the rate being dependent on the setting of the study and ethnical background of the subjects. As Jana Vrbikova (Prague, Czech Republic) and Vojtech Hainer [3] point out, nearly 30% of morbidly obese women, in contrast to only 5% of the same-sexed lean population, have PCOS. In their review the authors dwell on the links between obesity and polycystic ovary syndrome, classificatory and diagnostic aspects, cardiovascular risk factors, psychological issues, and treatment approaches. In our editorial (see above), we pointed out the recent advances pertaining to the identification of obesity polygenes based on genome-wide association studies. Anne-Kathrin Wermter (Marburg, Germany) et al. [4] report on negative results for the procolipase gene which is involved in dietary fat absorption, regulation of fat intake and body weight in rodents. The gene was screened for mutations in 93 extremely obese children and adolescents and a similar number of underweight young adults. Identified sequence variants were subsequently genotyped in larger samples of extremely obese children and adolescents, healthy normal and underweight young adults, and in nuclear families. Five identified sequence variants proved to be non-synonymous. The subsequent genotyping efforts did not reveal evidence for an association of CLPS SNPs with obesity or percentage of dietary fat intake. The limitations inherent to candidate gene studies apply. Many of us are familiar with extremely obese patients who during usually self-imposed diets have lost substantial amounts of body weight. In such individuals, weight loss can exceed 50 kg; the health of such individuals can be endangered by this radical weight loss. Heike Wolter (Berlin, Germany) et al. [5] report on a 15-year-old female who initially weighed 100 kg and who lost almost 40 kg within a period of 4 months. The adolescent had initiated weight loss in the belief that being thin would make her a better person. However, she lost control of her weight loss efforts, implying that she was not able to return to a normal eating behavior, and reported an intense fear of gaining weight. Furthermore, the patient revealed a body image distortion and secondary amenorrhea. According to DSM-IV, four criteria are used to diagnose anorexia nervosa. Because the adolescent fulfilled three of these (only the weight criterion was not met), she received a diagnosis of atypical anorexia nervosa. This case report illustrates our scant knowledge of the diagnostic crossover from obesity to atypical anorexia nervosa and other eating disorders. Subcutaneous fat pad size can be reduced via subcutaneous injection of a phosphatidylcholine preparation, also known as 'injection lipolysis'. Jürgen Janke (Berlin, Germany) an co-workers [6] studied the cellular effects of such a drug used in Germany for this purpose. Human preadipocytes, adipocytes, vascular and skeletal muscle cells as well as renal epithelial cells were incubated with the compound. Upon use of the undiluted compound, more than 90% of cell death occurred after 90 s in preadipocytes, after 6 min in vascular smooth muscle cells, skeletal myotubes and renal epithelial cells, and after 15 min in adipocytes. The authors conclude that the compound reduces subcutaneous fat pad size through cell and tissue destruction. Apart from the fact that a clear risk-benefit analysis is lacking, the drug is used off-label; the subcutaneous application represents a contraindicated route. The respective drug is currently approved in Italy, Germany, and Czech Republic. However, only intravenous application is approved for prevention and treatment of fat embolism after large trauma or large bone surgery and for treatment of peripheral vascular disease. Regulatory agencies have issued strong warnings on the use of this drug for subcutaneous injections. Nevertheless, a widespread use must be expected. Virginia Paul-Ebhohimhen (Aberdeen, UK) and Alison Avenell [7] searched seven electronic databases and two journals and reviewed secondary references based on a priori criteria to systematically review the effectiveness of group versus individual treatments for adult obesity. Eleven comparison groups from five qualifying trials were obtained with a total of 336 participants. Weight loss at 12
